Latest Endocyte Inc (ECYT) Headlines
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:04AM CST
Alcobra Ltd. was a big mover last session, as the company saw its shares rise by over 8% on the day.
Orphan Drug for Alexion's Soliris in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 5:05PM CST
Alexion's Soliris was granted an orphan drug designation in the EU.
Endocyte to Present at Upcoming Conferences in March
GlobeNewswire - Tue Feb 25, 3:01PM CST
Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following upcoming investment conferences in March:
Endocyte's Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 10:30AM CST
Endocyte reported fourth quarter 2013 net loss per share of 8 cents, narrower than the Zacks Consensus Estimate of a loss of 13 cents.
IEEE-SA Joins Kantara Initiative Board of Trustees to Drive Identity Management Open Standards
Marketwire - Tue Feb 25, 10:03AM CST
Kantara Initiative, a global identity initiative community, announced today that IEEE-SA has joined the Kantara Initiative Board of Trustees. The IEEE Standards Association (IEEE-SA) joins innovators on the Kantara Board Members from CA, Experian, Internet Society, ForgeRock, Nomura Research Institute, Radiant Logic, Terena and Government of Canada.
The Endocyte Bear Thesis: Why March Will be a Bad Month
at The Street - Tue Feb 25, 8:00AM CST
An investor short Endocyte explains his negative view on the upcoming European approval decision in ovarian cancer and why the lung cancer study is likely to fail.
Amarin's Vascepa Gets 3-Year Exclusivity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:20PM CST
Amarin announced that Vascepa was given 3 years of marketing exclusivity by FDA in connection with the MARINE indication.
Why Endocyte, Inc. Shares Briefly Popped
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 24, 12:48PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company...
Endocyte Reports Fourth Quarter and Year End 2013 Financial Results and Provides Business Update
GlobeNewswire - Mon Feb 24, 6:30AM CST
- Committee for Medicinal Products for Human Use (CHMP) Opinion on Pending EU Marketing Authorization Applications for Vintafolide and Etarfolatide Expected in March Followed by Potential EU Launch -
OncoMed Commences Study on OMP-54F28 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:50PM CST
OncoMed Pharma announced that it has commenced the third phase Ib study on OMP-54F28 in patients with platinum-sensitive ovarian cancer
Exelixis Q4 Loss In Line with Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 11:04AM CST
Exelixis reported fourth quarter 2013 net loss per share of 38 cents, in line with the Zacks Consensus Estimate.
Onconova's Rigosertib Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:40PM CST
Onconov's rigosertib failed to meet its primary endpoint of significant improvement in median overall survival in the ONTIME study
Omeros Doses First Patient in a Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:00PM CST
Omeros announced that the first patient has been dosed in a second phase II study on candidate, OMS824
Can Shire (SHPG) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:38AM CST
Shire has seen its Zacks Rank move up from Neutral to Buy over the past four weeks
Endocyte, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:56PM CST
DHX Media Ltd. (TSX: DHX), a leading independent producer, distributor and licensor of mainly children's entertainment content, has signed a major new VOD "Video On Demand" deal with Midwest Tape-owned digital platform HOOPLA.
FDA Approves Shire's New Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 5:36PM CST
Shire recently received positive news when the FDA approved a third manufacturing facility at Massachusetts, U.S. for the production of active pharmaceutical ingredient (API) in type I Gaucher disease drug, Vpriv.
CHTP's Northera Gains FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 5:20PM CST
Chelsea Therapeutics gained accelerated approval from the FDA for Northera for the treatment of symptomatic neurogenic orthostatic hypotension
Ohr Pharmaceutical (OHRP) Catches Eye: Stock Rises 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:25AM CST
Ohr Pharmaceutical was a big mover last session, with shares rising over 10%.
Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:21AM CST
Durata Therapeutics, Inc. (DRTX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:04AM CST
Alcobra Ltd. was a big mover last session, as the company saw its shares rise by over 8% on the day.
Orphan Drug for Alexion's Soliris in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 5:05PM CST
Alexion's Soliris was granted an orphan drug designation in the EU.
Endocyte to Present at Upcoming Conferences in March
GlobeNewswire - Tue Feb 25, 3:01PM CST
Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following upcoming investment conferences in March:
Endocyte's Q4 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 10:30AM CST
Endocyte reported fourth quarter 2013 net loss per share of 8 cents, narrower than the Zacks Consensus Estimate of a loss of 13 cents.
IEEE-SA Joins Kantara Initiative Board of Trustees to Drive Identity Management Open Standards
Marketwire - Tue Feb 25, 10:03AM CST
Kantara Initiative, a global identity initiative community, announced today that IEEE-SA has joined the Kantara Initiative Board of Trustees. The IEEE Standards Association (IEEE-SA) joins innovators on the Kantara Board Members from CA, Experian, Internet Society, ForgeRock, Nomura Research Institute, Radiant Logic, Terena and Government of Canada.
The Endocyte Bear Thesis: Why March Will be a Bad Month
at The Street - Tue Feb 25, 8:00AM CST
An investor short Endocyte explains his negative view on the upcoming European approval decision in ovarian cancer and why the lung cancer study is likely to fail.
Amarin's Vascepa Gets 3-Year Exclusivity - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:20PM CST
Amarin announced that Vascepa was given 3 years of marketing exclusivity by FDA in connection with the MARINE indication.
Why Endocyte, Inc. Shares Briefly Popped
Sean Williams, The Motley Fool - Motley Fool - Mon Feb 24, 12:48PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company...
Endocyte Reports Fourth Quarter and Year End 2013 Financial Results and Provides Business Update
GlobeNewswire - Mon Feb 24, 6:30AM CST
- Committee for Medicinal Products for Human Use (CHMP) Opinion on Pending EU Marketing Authorization Applications for Vintafolide and Etarfolatide Expected in March Followed by Potential EU Launch -
OncoMed Commences Study on OMP-54F28 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 3:50PM CST
OncoMed Pharma announced that it has commenced the third phase Ib study on OMP-54F28 in patients with platinum-sensitive ovarian cancer
Exelixis Q4 Loss In Line with Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 11:04AM CST
Exelixis reported fourth quarter 2013 net loss per share of 38 cents, in line with the Zacks Consensus Estimate.
Onconova's Rigosertib Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:40PM CST
Onconov's rigosertib failed to meet its primary endpoint of significant improvement in median overall survival in the ONTIME study
Omeros Doses First Patient in a Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:00PM CST
Omeros announced that the first patient has been dosed in a second phase II study on candidate, OMS824
Can Shire (SHPG) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 7:38AM CST
Shire has seen its Zacks Rank move up from Neutral to Buy over the past four weeks
Endocyte, Inc.Corporate Event Announcement Notice
Wall Street Horizon - Wed Feb 19, 7:56PM CST
DHX Media Ltd. (TSX: DHX), a leading independent producer, distributor and licensor of mainly children's entertainment content, has signed a major new VOD "Video On Demand" deal with Midwest Tape-owned digital platform HOOPLA.
FDA Approves Shire's New Facility - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 5:36PM CST
Shire recently received positive news when the FDA approved a third manufacturing facility at Massachusetts, U.S. for the production of active pharmaceutical ingredient (API) in type I Gaucher disease drug, Vpriv.
CHTP's Northera Gains FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 5:20PM CST
Chelsea Therapeutics gained accelerated approval from the FDA for Northera for the treatment of symptomatic neurogenic orthostatic hypotension
Ohr Pharmaceutical (OHRP) Catches Eye: Stock Rises 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:25AM CST
Ohr Pharmaceutical was a big mover last session, with shares rising over 10%.
Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 8:21AM CST
Durata Therapeutics, Inc. (DRTX) was a big mover last session, as the company saw its shares rise by over 6% on the day.
